| Leukemia, Myelocytic, Acute
Venclexta vs Daurismo
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Venclexta vs Daurismo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDaurismo has a higher rate of injection site reactions vs Venclexta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Daurismo but not Venclexta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Venclexta
Daurismo
At A Glance
Oral
Once daily
BCL-2 inhibitor
Oral
Daily
Hedgehog pathway inhibitor
Indications
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
Dosing
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 5-week ramp-up starting at 20 mg, increasing to 400 mg orally once daily; used as monotherapy or in combination with acalabrutinib, obinutuzumab, or rituximab.
Leukemia, Myelocytic, Acute 3- or 4-day ramp-up to 400 mg orally once daily in combination with azacitidine or decitabine, or 600 mg orally once daily in combination with low-dose cytarabine, each in 28-day cycles.
Leukemia, Myelocytic, Acute 100 mg orally once daily on days 1-28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1-10 of each 28-day cycle; treat for a minimum of 6 cycles in the absence of unacceptable toxicity or loss of disease control.
Contraindications
- Concomitant use with strong CYP3A inhibitors at initiation and during the ramp-up phase in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma due to increased risk of tumor lysis syndrome
—
Adverse Reactions
Most common (>=20%) in CLL/SLL Neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, edema
Most common (>=30%) in AML Nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, hypotension
Serious Tumor lysis syndrome, febrile neutropenia, pneumonia, sepsis, hemorrhage
Most common (>=10%) Anemia, hemorrhage, febrile neutropenia, thrombocytopenia, fatigue, edema, mucositis, pyrexia, chest pain, musculoskeletal pain, muscle spasm, nausea, constipation, abdominal pain, diarrhea, vomiting, dyspnea, cough, decreased appetite, dysgeusia, dizziness, headache, rash, pneumonia, hyponatremia, platelet count decreased, weight decreased, white blood cell count decreased, atrial arrhythmia, renal insufficiency
Serious (>=5%) Febrile neutropenia, pneumonia, hemorrhage, anemia, sepsis
Pharmacology
BCL-2 inhibitor; venetoclax is a selective, orally bioavailable small-molecule that restores apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM and triggering mitochondrial outer membrane permeabilization and activation of caspases.
Glasdegib is a Hedgehog pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction, and exhibits concentration-dependent QTc prolongation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Venclexta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Daurismo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (11/12)
UnitedHealthcare
Venclexta
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Daurismo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Venclexta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Daurismo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Venclexta.
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VenclextaView full Venclexta profile
DaurismoView full Daurismo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.